Comparing direct oral anticoagulants and warfarin for atrial fibrillation, venous thromboembolism, and mechanical heart valves

Consultant Pharmacist

Volumn 30, Issue 11, 2015, Pages 644-656

  Marcy, Todd R ^a   Truong, Teresa ^a   Rai, Andrea ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b INTEGRIS Southwest Medical Center   (United States)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Direct oral anticoagulant; Edoxaban; Mechanical heart valve; Rivaroxaban; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ATRIAL FIBRILLATION; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MECHANICAL HEART VALVE; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; HEART VALVE PROSTHESIS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; HEART VALVE PROSTHESIS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84957886123     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2015.644     Document Type: Review

References (40)

1. Bristol-Myers Squibb Pharma Company. Coumadin (warfarin) package insert. Princeton, NJ: Bristol-Myers Squibb; October 2011.
2. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim; September 2014.
3. Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) package insert. Titusville, NJ: Janssen Pharmaceuticals; September 2014.
4. Bristol-Myers Squibb Pharma Company. Eliquis (apixaban) package insert. Princeton, NJ: Bristol-Myers Squibb; August 2014.
5. Daiichi Sankyo Co., LTD. Savaysa (edoxaban) Package Insert. Tokyo, Japan; January 2015.
6. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-51.
7. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin patients with atrial fibrillation. N Engl J Med 2011; 365:981-92.
8. Patel MR, Mahaffey K W, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-91.
9. Giugliano R.P., Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-104.
10. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-510.
11. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-97.
12. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-52.
13. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129:764-72.
14. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799-808.
15. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
16. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369:1406-15.
17. Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368:709-18.
18. Eikelboom J.W., Connolly SJ, Brueckmann M et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369:1206-14.
19. Larsen TB, Rasmussen LH, Skjoth F et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation. J Am Coll Cardiol 2013; 61:2264-73.
20. Larsen TB, Rasmussen LH, Gorst-Rasmussen A et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med 2014; 127:1172-8.
21. Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol 2014; 63:321-8.
22. Wolf PA, Abbott RD, Kannel WB Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987; 147:1561-4.
23. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke. JAMA 2001; 285:2864-70.
24. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 9th ed. Chest 2012; 141:e531S-75S.
25. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1-76.
26. Lip GYH, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 2014; 35:1844-55.
27. McConeghy KW, Bress A, Qato DM et al. Evaluation of dabigatran bleeding adverse reaction reports in the FDA Adverse Event Reporting System during the first year of approval. Pharmacotherapy 2014; 34:561-9.
28. Hernandez I, Baik SH, Pinera A et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015; 175:18-24.
29. Beckman MG, Hooper WC, Critchley SE et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38:S495-501.
30. Fiessinger JN, Huisman M V, Davidson BL et al. Ximelagatran vs. low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. JAMA 2005; 293:681-9.
31. Harel Z, Sholzberg M, Shah PS et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014; 25:431-42.
32. Mendell J, Zahir H, Matsushima N et al. Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13:331-42.
33. Mueck W, Stampfuss J, Kubitza D et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53:1-16.
34. Eikelboom J.W., Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation 2011; 123:2363-72.
35. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-17.
36. Lyman GH, Khorana AA, Kuderer N et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013; 31:2189-204.
37. Patel MR, Hellkamp AS, Lokhnygina Y et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2013; 61:651-8.
38. Granger CB, Alexander JH, Hana M et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J 2012; 33 Suppl 1:685-6.
39. Ascani A, Lorio A, Agnelli G. Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coag Fibrinol 1999; 10:291-5.
40. Cundiff DK. Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med 2008; 10:258.